NP and the BOD did not meet performance standards last time at bat. Those shares went away permanently.
How do we assess the new performance. Is it a conga/limbo combo or is it somewhere in the fine print buried in a Rantes/CCR5/FDA/MHRA/CIA/FBI/CTIA report.